Novo Nordisk A/S (NYSE:NVO) Expected to Announce Quarterly Sales of $5.02 Billion

Wall Street brokerages expect Novo Nordisk A/S (NYSE:NVO) to announce sales of $5.02 billion for the current quarter, according to Zacks. Two analysts have made estimates for Novo Nordisk A/S’s earnings. The highest sales estimate is $5.12 billion and the lowest is $4.93 billion. Novo Nordisk A/S posted sales of $5.00 billion during the same quarter last year, which indicates a positive year-over-year growth rate of 0.4%. The firm is expected to issue its next earnings report on Wednesday, May 5th.

According to Zacks, analysts expect that Novo Nordisk A/S will report full year sales of $21.29 billion for the current financial year, with estimates ranging from $21.08 billion to $21.48 billion. For the next year, analysts expect that the business will report sales of $23.45 billion, with estimates ranging from $23.00 billion to $23.85 billion. Zacks’ sales calculations are a mean average based on a survey of analysts that cover Novo Nordisk A/S.

Novo Nordisk A/S (NYSE:NVO) last posted its quarterly earnings results on Tuesday, February 2nd. The company reported $4.01 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.60 by $3.41. The business had revenue of $5.15 billion during the quarter, compared to analysts’ expectations of $4.91 billion. Novo Nordisk A/S had a net margin of 32.65% and a return on equity of 71.46%.

A number of research analysts recently weighed in on NVO shares. UBS Group restated a “neutral” rating on shares of Novo Nordisk A/S in a report on Thursday, February 11th. Credit Suisse Group lowered shares of Novo Nordisk A/S from an “outperform” rating to a “neutral” rating in a report on Wednesday, January 20th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Novo Nordisk A/S in a research note on Friday, January 15th. They set a “buy” rating for the company. Finally, Barclays reaffirmed an “overweight” rating on shares of Novo Nordisk A/S in a report on Thursday, February 4th. Two equities research analysts have rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. Novo Nordisk A/S currently has a consensus rating of “Hold” and a consensus price target of $72.00.

NVO stock traded down $1.26 during mid-day trading on Friday, reaching $74.08. The company’s stock had a trading volume of 35,769 shares, compared to its average volume of 980,608. Novo Nordisk A/S has a fifty-two week low of $61.53 and a fifty-two week high of $75.86. The stock has a market cap of $174.44 billion, a PE ratio of 28.32, a P/E/G ratio of 2.21 and a beta of 0.46. The company’s 50 day moving average is $70.76 and its two-hundred day moving average is $70.37. The company has a current ratio of 1.04, a quick ratio of 0.78 and a debt-to-equity ratio of 0.04.

The firm also recently declared a semi-annual dividend, which was paid on Wednesday, April 7th. Investors of record on Monday, March 29th were given a dividend of $0.9494 per share. This represents a yield of 1.3%. This is a boost from Novo Nordisk A/S’s previous semi-annual dividend of $0.78. The ex-dividend date of this dividend was Friday, March 26th. Novo Nordisk A/S’s dividend payout ratio is 54.07%.

Several institutional investors have recently modified their holdings of the company. Childress Capital Advisors LLC bought a new stake in shares of Novo Nordisk A/S during the 4th quarter valued at about $35,000. Meeder Asset Management Inc. grew its position in shares of Novo Nordisk A/S by 1,221.4% during the 1st quarter. Meeder Asset Management Inc. now owns 555 shares of the company’s stock valued at $37,000 after buying an additional 513 shares during the last quarter. Capital Asset Advisory Services LLC acquired a new stake in shares of Novo Nordisk A/S in the fourth quarter valued at approximately $46,000. Perigon Wealth Management LLC bought a new position in Novo Nordisk A/S in the 4th quarter worth approximately $47,000. Finally, Asset Dedication LLC increased its position in Novo Nordisk A/S by 1,897.4% in the 1st quarter. Asset Dedication LLC now owns 759 shares of the company’s stock valued at $51,000 after acquiring an additional 721 shares during the period. Institutional investors and hedge funds own 5.91% of the company’s stock.

About Novo Nordisk A/S

Novo Nordisk A/S, a healthcare company, engages in the research, development, manufacture, and marketing of pharmaceutical products worldwide. It operates in two segments, Diabetes and Obesity care, and Biopharm. The Diabetes and Obesity care segment provides products in the areas of insulins, GLP-1 and related delivery systems, oral antidiabetic products, obesity, and other chronic diseases.

Featured Article: Find a Trading Strategy That Works

Get a free copy of the Zacks research report on Novo Nordisk A/S (NVO)

For more information about research offerings from Zacks Investment Research, visit

Earnings History and Estimates for Novo Nordisk A/S (NYSE:NVO)

Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with's FREE daily email newsletter.